HOME >> BIOLOGY >> NEWS
JCI Table of Contents, 15 August 2003

(known as EMT), the process of transformation from epithelial cells to matrix-producing fibroblasts, that may ultimately result in renal interstitial fibrosis and renal failure. EMT is regulated by numerous hormones and growth factors, including tumor growth factor beta1 (TGF-beta1). Youhua Liu and colleagues from the University of Pittsburgh School of Medicine demonstrate that expression of the intracellular enzyme integrin-linked kinase (ILK) is specifically induced in renal tubular epithelial cells in response to TGFbeta1 and that ILK administration induces many key events in TGFbeta1-induced EMT. The data implicate ILK as a crucial mediator of EMT in renal interstitial fibrosis. The authors demonstrate that administration of a kinase-dead form of ILK abolishes TGFbeta1-induced EMT suggesting that this and other inhibitors of ILK signaling could be explored as potential therapies for chronic renal disease.

TITLE: Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis

AUTHOR CONTACT:
Youhua Liu
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Phone: (412) 648-8263
Fax: (412) 648-1916
E-mail: liuy@msx.upmc.edu

View the PDF of this article at: https://www.the-jci.org/press/17913.pdf


Interfering interferons in medulloblastoma

Type I interferons (IFN-alpha and IFN-beta), crucial for fighting viral infection and regulating immune function, signal via activation of STAT1 and STAT2. Iain Campbell and colleagues from the Scripps Institute in La Jolla, California, show that in mice lacking STAT2, IFN-alpha retains potent biological activity in the central nervous system. IFN-alpha mediates a type Ilike immune response with IFN-gamma gene expression and signaling in the brain associated wit
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Aug-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
Cached News: